Nori Appointed to Cornell Department of Radiation Oncology

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

FLUSHING, NY--The New York Hospital-Cornell Medical Center has appointed Dattatreyudu Nori, MD, a pioneer in the subspecialty of brachytherapy, to the position of professor and chairman of the Department of Radiation Oncology.

FLUSHING, NY--The New York Hospital-Cornell Medical Center hasappointed Dattatreyudu Nori, MD, a pioneer in the subspecialtyof brachytherapy, to the position of professor and chairman ofthe Department of Radiation Oncology.

Dr. Nori will remain as professor and chairman of the Departmentof Radiation Oncology and director of Oncology at The New YorkHospital Medical Center of Queens, which is affiliated with theNew York Hospital-Cornell Medical Center and is a member of theNew York Hospital Care Network.

In his new position, Dr. Nori will direct the department's clinicalactivities, its research program, and the training of residentphysicians in radiation oncology.

He will also oversee the administration of the radiation oncologyprograms for the New York Hospital Care Network's 13 member hospitals.The combined network program will be one of the largest in thecountry, providing state-of-the-art radiation treatments to morethan 3,000 new patients each year.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content